Table 1 Characteristics of the studies about panobinostat combined with other agents for patients with relapsed/refractory multiple myeloma.
Study | Year | Study design | Total No. | Female/Male (n) | Mean age (y) | ISS stage:1/2/3/unknown | Dose of panobinostat | Combined agents | ORR |
|---|---|---|---|---|---|---|---|---|---|
Chari | 2015 | phase II | 20 | – | 64 | – | 20 mg | Len&DXM | 0.45 |
Berdeja | 2015 | phase I/II | 42 | 25/17 | 66 | 20/14/5/5 | 20–30 mg | CFZ | 0.67 |
San-Miguel | 2014 | phase III | 387 | 185/202 | 63 | 156/104/77/50 | 20 mg | BTZ&DXM | 0.61 |
Mangiacavalli | 2014 | phase II | 15 | – | – | – | 20 mg | BTZ&DXM | 0.67 |
Kaufman | 2014 | phase I | 20 | – | 64.5 | – | 15–20 mg | CFZ | 0.50 |
Berenson | 2014 | phase I/II | 40 | 15/25 | 65.4 | – | 10–20 mg | Mel | 0.09 |
San-Miguel | 2013 | phase Ib | 62 | 19/43 | 62 | 25/15/20/2 | 10–20 mg | BTZ&DXM | 0.52 |
Richardson | 2013 | phase II | 55 | 26/29 | 61 | 18/23/13/1 | 20 mg | BTZ&DXM | 0.35 |
Zangari | 2012 | phase I | 11 | – | 58 | – | 5–15 mg | BTZ | 0.36 |
Shah | 2012 | phase Ib | 17 | 6/11 | 62 | – | 15 mg | CFZ | 0.35 |
Offidani | 2012 | phase II | 31 | 15/16 | 68 | 17/10/4/0 | 10–20 mg | Mel&PED&Tha | 0.39 |
